RheumNow Week in Review - 3 June 2016 Save
This week's highlights from RheumNow.com include:
- In a study of knee OA patients they examined the frequency of venous thrombotic events (VTE) (n=4020) and compared with controls having VTE(1:5). NSAID use (diclofenac, meloxicam, ibuprofen, coxibs; but not naproxen) was associated with a ~40% increase VTE risk. https://t.co/itQexYqRk8
- Myositis experts consensus says that after steroids, azathioprine, methotrexate and mycophenolate are most commonly chosen agents to manage myositis. https://t.co/wboHZ7dJQe
- FDA rules to lower salt content by manufacturers & restaurants – recommending a decrease in daily salt intake from 3.4 to 2.3 g/day. https://t.co/wJC7G5DNZS
- 1487 patients with low back pain were reviewed for their medication use. Low rates of med use found: only 18.7% taking meds for back pain; anxiolytics 14%; NSAIDs 12%; analgesic 7%; muscle relaxants 3%; opioids 1.6%. https://t.co/oJH6DCWP0D
- Recurrent acute anterior uveitis responds to golimumab 50 mg qmo; 12/15 eyes from B27+ AS patients improve, going into remission https://t.co/0ttwTe56zv
- Samsung Bioepis has a new biosimilar “Flixabi” (a Remicade biosimilar) approved for all 6 indications in 28 EU states & Norway, Iceland. https://t.co/oHwkbozHSG
- Morning Stiffness Madness - Dr. Cush debunks the importance of morning stiffness as an inflammatory indicator.
- Patient Reluctance to Take Bisphosphonates
- Lower GI Perforation Risk Noted for Tofacitinib and Tocilizumab
ADD THE FIRST COMMENT
Disclosures
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.